<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04619342</url>
  </required_header>
  <id_info>
    <org_study_id>20304-0-01</org_study_id>
    <nct_id>NCT04619342</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)</brief_title>
  <official_title>Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT): A Single Center, Open, Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tsinghua Chang Gung Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tsinghua Chang Gung Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of&#xD;
      GSMs-TACE Combined with Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC)&#xD;
      with Type III Portal Vein Tumor Thrombus (PVTT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival（PFS）</measure>
    <time_frame>6 months</time_frame>
    <description>PFS is defined as the time from Day 1 of treatment until the progression of a target lesion or the appearance of new lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Overall Survival (mOS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3, 6, 12 and 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)</condition>
  <arm_group>
    <arm_group_label>GSMs-TACE+ Surgical Resection Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After TACE using epirubicin and GSMs (150-350μm or 350-560μm), patients that meet certain criteria will receive surgical resection of PVTT, as specified per protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSMs-TACE Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive TACE using epirubicin and GSMs (150-350μm or 350-560μm), as specified per protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GSMs-TACE</intervention_name>
    <description>TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)</description>
    <arm_group_label>GSMs-TACE Group</arm_group_label>
    <arm_group_label>GSMs-TACE+ Surgical Resection Group</arm_group_label>
    <other_name>TACE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Resection</intervention_name>
    <description>Surgical Resection of PVTT</description>
    <arm_group_label>GSMs-TACE+ Surgical Resection Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of HCC with PVTT involving the main portal vein, i.e. Type III&#xD;
             PVTT according to Cheng's classification.&#xD;
&#xD;
          2. Confirmed abundant blood supply of tumor thrombus using Computed Tomography (CT) and&#xD;
             Magnetic Resonance Imaging (MRI).&#xD;
&#xD;
          3. The tumor must be surgically resectable.&#xD;
&#xD;
          4. ECOG Performance Status 0-2.&#xD;
&#xD;
          5. Adequate liver function (Child-Pugh class A)&#xD;
&#xD;
          6. Life expectancy ≥ 3 months&#xD;
&#xD;
          7. Previous physical ablation is allowed.&#xD;
&#xD;
          8. Age 18 to 75 years&#xD;
&#xD;
          9. Able to sign and provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients previously took oral molecular targeted drug or received immunotherapy.&#xD;
&#xD;
          2. Patients with arteriovenous fistula.&#xD;
&#xD;
          3. Severe active infection &gt;grade 2 (except for Hepatitis B and C infection).&#xD;
&#xD;
          4. Concomitant malignant tumors in other organs.&#xD;
&#xD;
          5. Presence of severe cardiac, lung or kidney disease.&#xD;
&#xD;
          6. Pregnant or breast-feeding woman.&#xD;
&#xD;
          7. Patients with severe neuropathy and unable to report therapeutic effects.&#xD;
&#xD;
          8. Patients with severe atherosclerosis.&#xD;
&#xD;
          9. Patients with AIDS.&#xD;
&#xD;
         10. Severe hemorrhage of digestive tract within the 4 weeks prior to enrolment.&#xD;
&#xD;
         11. Severe thrombogenesis or embolic event within the 6 months prior to enrolment.&#xD;
&#xD;
         12. Currently enrolled or going to enroll in any other clinical trials.&#xD;
&#xD;
         13. Subject is not suitable to participate in the study as judged by investigator (poor&#xD;
             patient compliance, inability to follow up).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuewei Zhang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tsinghua Changgeng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuewei Zhang</last_name>
    <phone>00861800115669</phone>
    <email>zhangyuewei1121@sina.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuewei Zhang</last_name>
      <phone>00861800115669</phone>
      <email>zhangyuewei1121@sina.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

